(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy. Cancer immunotherapy broadly includes passive immunization, active...
Read More »
Posts Tagged ‘ Bristol-Myers Squibb Company ’
Allos Therapeutics
ALTH
AMAG
AMAG Pharmaceuticals
American Society of Clinical Oncology
Amgen
AMGN
Amicus Therapeutics
AMLN
ASCO
BIIB
Biogen Idec
biotech
biotechnology
BMY
cancer
CELG
Celgene
CEPH
Cephalon
Cougar Biotechnology
CYCC
Cyclacel Pharmaceuticals
Dendreon
DNDN
Eli Lilly & Co
FOLD
genentech
GENZ
GlaxoSmithKline
GSK
HGSI
life sciences
LLY
OSIR
Osiris Therapeutics
PFE
Pfizer
prostate cancer
Provenge
roche
Seattle Genetics
SGEN
SNY
Soligenix
Cancer Vaccine Therapies: Failures and Future Opportunities
Biotech Deal Activity Declines…The Pause that Refreshes?
* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies. For industry executives and investors, the annual event serves as a good barometer for the rest of...
Read More »







